MX2019000199A - Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas. - Google Patents
Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas.Info
- Publication number
- MX2019000199A MX2019000199A MX2019000199A MX2019000199A MX2019000199A MX 2019000199 A MX2019000199 A MX 2019000199A MX 2019000199 A MX2019000199 A MX 2019000199A MX 2019000199 A MX2019000199 A MX 2019000199A MX 2019000199 A MX2019000199 A MX 2019000199A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- pyrimidin
- heteroaryl
- amines
- synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invención es del área de la síntesis de compuestos basados en pirimidina, útiles en el tratamiento de trastornos que implican proliferación celular anormal que incluyen, sin limitación, tumores y cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357797P | 2016-07-01 | 2016-07-01 | |
PCT/US2017/040102 WO2018005865A1 (en) | 2016-07-01 | 2017-06-29 | Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000199A true MX2019000199A (es) | 2019-09-23 |
Family
ID=60786476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000199A MX2019000199A (es) | 2016-07-01 | 2017-06-29 | Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10865210B2 (es) |
EP (1) | EP3478295A4 (es) |
JP (1) | JP7106462B2 (es) |
KR (1) | KR102445288B1 (es) |
CN (1) | CN109789142B (es) |
AU (2) | AU2017290362B2 (es) |
BR (1) | BR112018077155A2 (es) |
CA (1) | CA3028752A1 (es) |
EA (1) | EA201990189A1 (es) |
IL (1) | IL263911B (es) |
MX (1) | MX2019000199A (es) |
NZ (1) | NZ749275A (es) |
WO (1) | WO2018005865A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
KR102576011B1 (ko) | 2017-01-06 | 2023-09-06 | 쥐원 쎄라퓨틱스, 인크. | 암의 치료를 위한 조합 요법 |
JP2020527593A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. | 1,8−ナフチリジノン化合物およびその使用 |
US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
CN108299317A (zh) * | 2018-03-20 | 2018-07-20 | 爱斯特(成都)生物制药股份有限公司 | 1,4-二氮杂螺[5,5]十一烷盐酸盐的合成方法 |
WO2019199883A1 (en) * | 2018-04-09 | 2019-10-17 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
CN108840814B (zh) * | 2018-07-24 | 2021-09-24 | 南京药石科技股份有限公司 | 一种8-氧代-2,6,9-三氮杂螺[4.5]癸烷-2-羧酸叔丁酯制备方法 |
SG11202101807SA (en) * | 2018-08-24 | 2021-03-30 | G1 Therapeutics Inc | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
JP2022523473A (ja) | 2019-01-18 | 2022-04-25 | ニューベイション・バイオ・インコーポレイテッド | 1,8-ナフチリジジノン化合物およびそれらの使用 |
MX2022014573A (es) | 2020-05-19 | 2022-12-15 | G1 Therapeutics Inc | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos. |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
EP4164653A1 (en) * | 2020-06-15 | 2023-04-19 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
US20230374028A1 (en) | 2020-10-08 | 2023-11-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of trilaciclib and of trilaciclib salts |
CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
CN113754600A (zh) * | 2021-11-10 | 2021-12-07 | 天津敬康生物科技有限公司 | 1,4-二氮杂螺[5,5]十一烷-3-酮的制备方法 |
CN114014863B (zh) * | 2021-12-21 | 2022-11-29 | 武汉九州钰民医药科技有限公司 | 骨髓保护剂曲拉西利的制备方法 |
CN114014864B (zh) * | 2021-12-21 | 2022-11-25 | 武汉九州钰民医药科技有限公司 | 一种曲拉西利化合物的制备工艺 |
WO2023164255A1 (en) * | 2022-02-28 | 2023-08-31 | Teva Pharmaceuticals International Gmbh | Crystalline forms of trilaciclib and trilaciclib salts |
US11970403B2 (en) * | 2022-06-27 | 2024-04-30 | Saudi Arabian Oil Company | Method of zeolite synthesis including pH-modified water-soluble oxidized disulfide oil composition |
US11958751B2 (en) * | 2022-06-27 | 2024-04-16 | Saudi Arabian Oil Company | Method of synthesizing materials integrating supernatant recycle |
CN115477653B (zh) * | 2022-10-11 | 2024-04-09 | 安徽省庆云医药股份有限公司 | 一种曲拉西利关键中间体及曲拉西利的制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506760B1 (en) * | 2000-04-14 | 2003-01-14 | Corvas International, Inc. | Substituted hydrazinyl heteroaromatic inhibitors of thrombin |
WO2002012238A2 (en) * | 2000-08-04 | 2002-02-14 | Warner-Lambert Company | 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
CA2498566A1 (en) * | 2002-09-11 | 2004-06-10 | Merck & Co., Inc. | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
RU2351599C2 (ru) | 2004-01-08 | 2009-04-10 | Ф.Хоффманн-Ля Рош Аг | Диазаспиропиперидиновые производные в качестве ингибиторов глицинового переносчика 1 и глицинового переносчика 2 |
AU2005282466B2 (en) | 2004-09-08 | 2011-03-10 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam CGRP receptor antagonists |
US7696192B2 (en) | 2004-09-09 | 2010-04-13 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirolactam CGRP receptor antagonists |
US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
EP1797073B1 (en) | 2004-09-13 | 2010-04-14 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam cgrp receptor antagonists |
US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
AU2006316627A1 (en) | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirolactam aryl CGRP receptor antagonists |
US7951795B2 (en) | 2006-12-08 | 2011-05-31 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
US8153393B2 (en) | 2007-03-02 | 2012-04-10 | University Of Massachusetts | Spirolactam targeting compounds and related compounds |
KR20110002475A (ko) * | 2008-04-22 | 2011-01-07 | 아스트라제네카 아베 | 치환 피리미딘-5-카르복시아미드 281 |
BRPI0917791B1 (pt) | 2008-08-22 | 2022-03-22 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação |
HUE030714T2 (en) | 2010-10-25 | 2017-05-29 | G1 Therapeutics Inc | CDK inhibitors |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
US8829102B2 (en) | 2010-10-27 | 2014-09-09 | Cabot Corporation | High loading carbon black masterbatch for pressure pipe applications |
CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
CA2870019C (en) | 2012-04-26 | 2020-08-18 | Francis Xavier Tavares | Synthesis of lactams |
EP2846798B1 (en) | 2012-05-09 | 2018-04-04 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
WO2014144596A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
JP6575952B2 (ja) | 2013-04-08 | 2019-09-18 | ファーマサイクリックス エルエルシー | イブルチニブ併用療法 |
US20150031674A1 (en) * | 2013-07-26 | 2015-01-29 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
US9481591B1 (en) | 2013-12-16 | 2016-11-01 | Barbara Blake | Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water |
US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
CN105622638B (zh) | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
RU2726631C1 (ru) | 2017-01-23 | 2020-07-15 | Пфайзер Инк. | Гетероциклические спиросоединения в качестве ингибиторов magl |
-
2017
- 2017-06-29 NZ NZ749275A patent/NZ749275A/en unknown
- 2017-06-29 CA CA3028752A patent/CA3028752A1/en active Pending
- 2017-06-29 CN CN201780041253.5A patent/CN109789142B/zh active Active
- 2017-06-29 KR KR1020197002844A patent/KR102445288B1/ko active IP Right Grant
- 2017-06-29 MX MX2019000199A patent/MX2019000199A/es unknown
- 2017-06-29 AU AU2017290362A patent/AU2017290362B2/en active Active
- 2017-06-29 EA EA201990189A patent/EA201990189A1/ru unknown
- 2017-06-29 EP EP17821293.2A patent/EP3478295A4/en active Pending
- 2017-06-29 BR BR112018077155-4A patent/BR112018077155A2/pt active Search and Examination
- 2017-06-29 WO PCT/US2017/040102 patent/WO2018005865A1/en unknown
- 2017-06-29 JP JP2018569090A patent/JP7106462B2/ja active Active
-
2018
- 2018-12-21 US US16/230,381 patent/US10865210B2/en active Active
- 2018-12-23 IL IL263911A patent/IL263911B/en unknown
-
2020
- 2020-12-14 US US17/121,392 patent/US11629150B2/en active Active
-
2021
- 2021-11-03 AU AU2021261879A patent/AU2021261879B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017290362B2 (en) | 2021-08-05 |
JP2019520380A (ja) | 2019-07-18 |
RU2019102643A (ru) | 2020-08-03 |
IL263911B (en) | 2021-10-31 |
CA3028752A1 (en) | 2018-01-04 |
CN109789142B (zh) | 2022-08-23 |
EP3478295A4 (en) | 2019-12-04 |
CN109789142A (zh) | 2019-05-21 |
BR112018077155A2 (pt) | 2019-04-02 |
US20210122755A1 (en) | 2021-04-29 |
KR20190025651A (ko) | 2019-03-11 |
AU2021261879A1 (en) | 2021-12-02 |
EP3478295A1 (en) | 2019-05-08 |
AU2017290362A1 (en) | 2019-01-17 |
IL263911A (en) | 2019-01-31 |
AU2021261879B2 (en) | 2024-01-04 |
NZ749275A (en) | 2023-06-30 |
US11629150B2 (en) | 2023-04-18 |
US20190135820A1 (en) | 2019-05-09 |
KR102445288B1 (ko) | 2022-09-19 |
US10865210B2 (en) | 2020-12-15 |
RU2019102643A3 (es) | 2020-08-21 |
EA201990189A1 (ru) | 2019-06-28 |
WO2018005865A1 (en) | 2018-01-04 |
JP7106462B2 (ja) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000199A (es) | Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas. | |
MX2019000200A (es) | Agentes antiproliferativos basados en pirimidina. | |
PH12018502710A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12019501443A1 (en) | Benzooxazole derivatives as immunomodulators | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
PH12016501107A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
NZ733948A (en) | Sulfonylureas and related compounds and use of same | |
EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
EA201891526A3 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
MX362215B (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
GEP20227344B (en) | Pyrimidine compound as jak kinase inhibitor | |
EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
EA201790603A1 (ru) | Ингибиторы гистондеметилазы | |
WO2017027359A8 (en) | Pyridines and their use in the treatment of cancer | |
MX2019009356A (es) | Sulfinilpiridinas y su uso en el tratamiento del cancer. | |
MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
EA201790604A1 (ru) | Ингибиторы гистондеметилазы | |
IN2014DE00554A (es) | ||
MX2020002222A (es) | Arginina deiminasa encapsulada dentro de eritrocitos y su uso en el tratamiento de cancer y la deficiencia de arginasa-1. | |
MX2020000491A (es) | Moduladores terapeuticos del modo inverso de la atp sintasa. |